192650-79-6

Upstream product

• 1428761-25-4 methyl 2-(2-chloro-5-methyl-4-nitrophenyl)acetate 
• 1428761-24-3 2-(2-chloro-5-methyl-4-nitrophenyl)acetic acid 
• 1428761-23-2 1-allyl-2-chloro-5-methyl-4-nitrobenzene 
• 57310-39-1 2-bromo-1-chloro-4-methylbenzene 

Downstream Products

• 1432909-83-5 methyl 2-(2-chloro-5-methyl-4-(6-methylpyrazin-2-yl)phenyl)acetate 
• 1432909-81-3 methyl 2-(2-chloro-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate 
• 1432909-88-0 methyl 2-(2-chloro-5-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)acetate 
• 1428761-26-5 methyl 2-(4-bromo-2-chloro-5-methylphenyl)acetate 
• 1428761-27-6 methyl 2-(2-chloro-5-methyl-4-(pyridin-3-yl)phenyl)acetate 
• 1432909-86-8 methyl 2-(2-chloro-4-(N-hydroxycarbamimidoyl)-5-methylphenyl)acetate 
• 1432909-85-7 methyl 2-(2-chloro-4-cyano-5-methylphenyl)acetate 

Relevant academic research and scientific papers

8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.

PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of cell proliferative disorders and/or CNS disorders.